[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-onset-latency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-onset-latency":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100623070","circadian-light-exposure-adjustment-for-restfulness-100623070",false,"NCT07391852","Circadian Light Exposure Adjustment for Restfulness","CLEAR","Inclusion Criteria:\n\n* Inclusion requires that children are aged 5.0-6.9 years at the time of enrollment with a parent-reported sleep onset of ≥ 60 min after parents' desired bedtime at least three nights per week.\n\nOne adult parent of each participating child will also take part in the study. Parents must be able to provide consent for themselves and their child and to complete the interview at the end of the study.\n\nExclusion Criteria:\n\n* Children are excluded for the following reasons:\n\n  * All sleep disorders as indicated on the telephone screener or by clinical cut-off scores on the Children's Sleep Habits Questionnaire (CSHQ), except for insomnia or DSWPD as features of these disorders are directly targeted by the intervention. Secondary analyses will explore if outcomes differ among participants with or without parent-reported symptoms consistent with these diagnoses.\n  * Physical abilities that interfere with assessments (e.g., visual impairment), developmental disabilities (e.g., autism, attention-deficit\u002Fhyperactivity disorder (ADHD), pervasive developmental disorder), epilepsy or other neurological disorders, metabolic disorders, medical conditions that commonly require treatments or assessments during the night (e.g., cancer, diabetes, active asthma), current infection or lead poisoning; a head injury involving loss of consciousness in the past 6 months.\n  * Current use of medications affecting daytime sleepiness, the circadian system, or light sensitivity.\n  * Eye disorders or color blindness (determined with Ishihara Color Vision Test); corrected vision with eyeglasses is permitted.","ALL","60 Months","83 Months",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Many young children are exposed to light int he evening hours before bedtime. Children's biological clocks are highly sensitive to evening light exposure, which can delay the timing of the clock and make it harder to fall asleep. The purpose of this study is to test three strategies (adjustment to home lighting, amber-tinted glasses, clear glasses) to reduce evening light exposure in children ages 5-6 years with parent-reported sleep onset difficulties in order to improve their sleep and the timing of their biological clock. This study takes place over approximately 5 weeks. After baseline assessments of children's sleep timing, light exposure, cognition, and circadian rhythms, they will be randomly assigned to one of three interventions to reduce evening light exposure for two weeks. After the two-week intervention period, the baseline measures are repeated and parents are interviewed about their and their child's experiences with the intervention.",[27],"Sleep Onset Latency",[29,30,31,32,33,34,35],"Behavioral sleep problems","Circadian phase","sleep onset latency","Early childhood","dim light melatonin onset (DLMO)","Evening light exposure","Light intervention","NOT_YET_RECRUITING","2026-01-29",{"date":39,"type":40},"2026-02-06","ACTUAL",{"date":42,"type":21},"2026-01-15",{"date":44,"type":21},"2030-07-31",{"name":46,"class":47},"University of Arizona","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100608331","study-of-the-efficacy-of-dietary-supplementation-in-targeting-sleep-quality-nutrisom-01b-100608331","NCT07200167","Study of the Efficacy of Dietary Supplementation in Targeting Sleep Quality (NutriSom-01B)","Study of the Efficacy of Dietary Supplementation in Targeting Sleep Quality (NutriSom Study B)","NutriSom-01B","Inclusion criteria:\n\n* subject Informed consent form (ICF) is signed\n* aged 24-65 years at the time of the signature of ICF\n* suboptimal sleep quality according to Pittsburgh Sleep Quality Index (PSQI-SI): PSQI \\> 5\n* no clinically significant (subthreshold) insomnia according to Pittsburgh Sleep Quality Index (PSQI-SI) (Kmetec et al., 2022): PSQI \\\u003C= 9\n* a body mass index (BMI) \\\u003C= 32 kg\u002Fm2\n* stable medications for non excluded concurrent medical conditions for six weeks prior to the screening visit\n* ability to ingest oral food supplement (study product)\n* willing to follow all study procedures, including attending all site visits and use of actigraphy\n\nExclusion criteria:\n\n* diagnosed or subject to therapy due to sleep disorders\n* acute infectious disease\n* any kind of chronic pharmacological therapy with antihypertensives or antidepressants\n* any kind of other pharmacological therapy that could interact with active ingredients used in the study\n* pregnancy or planned pregnancy, lactation, menopause (with pharmacological treatment)\n* use of beta-blockers\n* chronic use of use of prostaglandin synthesis inhibitors (nonsteroidal anti-inflammatory drugs), such as acetylsalicylic acid and ibuprofen\n* supplementation with melatonin or other food supplements intendent for sleep quality during last 2 weeks\n* unwillingness to maintain caffeine abstinence after 4:00 PM during the study\n* not having a mobile upper extremity for attaching an actigraph\n* known alcohol and\u002For drug abuse\n* unwillingness to comply with the maximum limit of 2 alcoholic drinks per day, and only up to 1 alcoholic drink after 6:00 PM during the study\n* known lactose\u002Fgluten intolerances\u002Ffood allergies\n* known gastrointestinal disease\n* less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)\n* have stomach or bowel resection\n* night work or work shifts with night work\n* mental incapacity that precludes adequate understanding or cooperation\n* participation in another investigational study",true,"24 Years","65 Years",{"count":61,"type":21},70,[24],"single-center, randomized, cross over, double-blind, placebo controlled intervention study",[27,65],"Sleep Quality",[67,68,69,31,70,71,72,73],"melatonin","supplementation","sleep","actigraphy","sleep quality","sleep efficiency","valerian","2025-09-30",{"date":76,"type":40},"2025-10-06",{"date":78,"type":21},"2025-10-01",{"date":80,"type":21},"2026-10-30",{"name":82,"class":47},"Institute of Nutrition, Slovenia (Nutris)",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":63,"conditions":94,"keywords":95,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100562243","efficacy-of-dietary-supplementation-with-melatonin-in-targeting-sleep-quality-100562243","NCT06600633","Efficacy of Dietary Supplementation With Melatonin in Targeting Sleep Quality","Study of the Efficacy of Dietary Supplementation in Targeting Sleep Quality (NutriSom Study A)","NutriSom-01A","Inclusion criteria:\n\n* subject Informed consent form (ICF) is signed\n* aged 24-65 years at the time of the signature of ICF\n* suboptimal sleep quality according to Pittsburgh Sleep Quality Index (PSQI-SI): PSQI higher than 5\n* no clinically significant (subthreshold) insomnia according to Pittsburgh Sleep Quality Index (PSQI-SI) (Kmetec et al., 2022): PSQI up to 9\n* a body mass index (BMI) up to 32 kg\u002Fm2\n* stable medications for non excluded concurrent medical conditions for six weeks prior to the screening visit\n* ability to ingest oral food supplement (study product)\n* willing to follow all study procedures, including attending all site visits and use of actigraphy\n\nExclusion criteria:\n\n* diagnosed or subject to therapy due to sleep disorders\n* acute infectious disease\n* any kind of chronic pharmacological therapy with antihypertensives or antidepressants\n* any kind of other pharmacological therapy that could interact with active ingredients used in the study\n* pregnancy or planned pregnancy, lactation, menopause (with clinically relevant symptoms\u002Ftherapy)\n* use of beta-blockers\n* chronic use of use of prostaglandin synthesis inhibitors (nonsteroidal anti-inflammatory drugs), such as acetylsalicylic acid and ibuprofen\n* supplementation with melatonin or other food supplements intendent for sleep quality during last 2 weeks\n* unwillingness to maintain caffeine abstinence after 4:00 PM during the study\n* not having a mobile upper extremity for attaching an actigraph\n* known alcohol and\u002For drug abuse\n* unwillingness to comply with the maximum limit of 2 alcoholic drinks per day, and only up to 1 alcoholic drink after 6:00 PM during the study\n* known lactose\u002Fgluten intolerances\u002Ffood allergies\n* known gastrointestinal disease\n* less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)\n* have stomach or bowel resection\n* night work (including as part of shift work)\n* mental incapacity that precludes adequate understanding or cooperation\n* participation in another investigational study",{"count":92,"type":21},30,[24],[27,65],[67,68,69,31,70,71,72],"RECRUITING","2024-09-18",{"date":99,"type":40},"2024-09-20",{"date":101,"type":40},"2024-09-17",{"date":103,"type":21},"2025-09-17",{"name":82,"class":47}]